Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CLDN18.2 Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01630083
What this trial is testing

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

Who this might be right for
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of EsophagusCLDN18.2-positive Gastric Adenocarcinoma
Astellas Pharma Global Development, Inc. 252
Early research (Phase 1)Study completedNCT04400383
What this trial is testing

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Who this might be right for
Solid TumorGastric CancerPancreatic Adenocarcinoma
CARsgen Therapeutics Co., Ltd. 62
Large-scale testing (Phase 3)Looking for participantsNCT07584135
What this trial is testing

JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
NingBo Junyan Hongshi Biosciences Co., Ltd 600
Early research (Phase 1)Looking for participantsNCT06084286
What this trial is testing

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Sichuan University 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06446388
What this trial is testing

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumor
Qilu Pharmaceutical Co., Ltd. 360
Very early researchLooking for participantsNCT07595237
What this trial is testing

A IIT Study of 177Lu-DOTA-SNA040

Who this might be right for
Advanced Solid Tumors (Such as Gastric Cancer)Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)Advanced Solid Tumors (Such as Pancreatic Cancer)+1 more
SmartNuclide Biopharma 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07108504
What this trial is testing

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic CancerChemotherapy Effect
Shanghai Zhongshan Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT07432295
What this trial is testing

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Who this might be right for
Solid TumorAdvanced CancerMetastatic Cancer+3 more
I-Mab Biopharma US Limited 180
Testing effectiveness (Phase 2)Looking for participantsNCT07556640
What this trial is testing

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Who this might be right for
Gastric Cancer Stage IVPeritoneal Metastases From Gastric CancerGastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital 74
Early research (Phase 1)Looking for participantsNCT06350006
What this trial is testing

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Who this might be right for
CLDN18.2-positive Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd. 924
Testing effectiveness (Phase 2)Looking for participantsNCT07622940
What this trial is testing

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Who this might be right for
Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT05994001
What this trial is testing

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Who this might be right for
Biliary Tract CancerCandonilimabClaudin 18.2
Shanghai Zhongshan Hospital 78
Large-scale testing (Phase 3)Active Not RecruitingNCT06351020
What this trial is testing

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
LaNova Medicines Zhejiang Co., Ltd. 387
Early research (Phase 1)Ended earlyNCT04260191
What this trial is testing

Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric and Gastroesophageal Junction Adenocarcinoma
Amgen 15
Testing effectiveness (Phase 2)UnknownNCT06041035
What this trial is testing

QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Qilu Pharmaceutical Co., Ltd. 115
Not applicableLooking for participantsNCT07427992
What this trial is testing

Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
European Institute of Oncology 70
Testing effectiveness (Phase 2)Looking for participantsNCT07569068
What this trial is testing

Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital 88
Large-scale testing (Phase 3)Looking for participantsNCT07103668
What this trial is testing

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Who this might be right for
Gastric Adenocarcinoma
Suzhou Immunofoco Biotechnology Co., Ltd 150